Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against <i>Acinetobacter baumannii</i> in Patients with Hospital-Acquired Pneumonia

• Main Authors: Yingjie Zhou (Author), Jing Zhang (Author), Yuancheng Chen (Author), Jufang Wu (Author), Beining Guo (Author), Xiaojie Wu (Author), Yingyuan Zhang (Author), Minggui Wang (Author), Ru Ya (Author), Hao Huang (Author)
• Format: Book
• Published: MDPI AG, 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cefoperazone/sulbactam (CPZ/SUL) is a β-lactam and β-lactamase inhibitor combination therapy for the treatment of respiratory tract infections. Using data from a prospective, multiple-center, open-label clinical trial in 54 patients with hospital-acquired pneumonia or ventilator-associated pneumonia...